Compare Amphastar Pharmaceuticals Inc (AMPH) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Impinj Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Impinj Inc trades at $140.86 (market cap $4.39B). The key difference: Impinj Inc is far larger — about 5.3× Amphastar Pharmaceuticals Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | PI | |
|---|---|---|
Market Cap | $826.08M | $4.39B |
Sector | Health | Technology |
52-Week High | $30.81 | $241.91 |
52-Week Low | $16.87 | $91.34 |
Enterprise Value | $1.22B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Impinj (PI) trades at $144.03, down 0.26% today, with a bullish technical signal supported by moving averages and a golden cross pattern. The company reported Q1 2026 earnings of $0.14 per share, beating estimates, but faces negative net income margins and high valuation multiples. Recent news highlights insider selling and upcoming Q2 2026 results, while analyst consensus remains strongly bullish with a $167.50 price target.
The outlook for PI is mixed: strong analyst support and technical momentum suggest upside potential, but profitability challenges and high valuations pose risks. Investment opportunity hinges on execution improving margins and revenue growth, while key risks include competitive pressures and insider selling trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
